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Background and Objectives. Triple negative breast cancer (TNBC) has been shown to be generally chemosensitive. We sought to
investigate the utility ofmammography (MMG), ultrasonography (US), and breastmagnetic resonance imaging (MRI) in predicting
residual disease following neoadjuvant chemotherapy for TNBC. Methods. We identified 148 patients with 151 Stage I–III TNBC
treatedwith neoadjuvant chemotherapy. Residual tumor size was estimated byMMG,US, and/orMRI prior to surgical intervention
and compared to the subsequent pathologic residual tumor size. Data were compared using chi-squared test.Results. Of 151 tumors,
44 (29%) did not have imaging performed prior to surgical treatment.Thirty-eight (25%) tumors underwent a pathologic complete
response (pCR), while 113 (75%) had residual invasive disease. The imaging modality was accurate to within 1 cm of the final
pathologic residual disease in 74 (69%) cases and within 2 cm in 94 (88%) cases. Groups were similar with regards to patient age,
race, tumor size and grade, and clinical stage (𝑃 > 0.05). Accuracy to within 1 cm was the highest for US (83%) and the lowest
for MMG (56%) (𝑃 < 0.05). Conclusions. Breast US and MRI were more accurate than MMG in predicting residual tumor size
following neoadjuvant chemotherapy in patients with TNBC. None of the imaging modalities were predictive of a pCR.
1. Introduction
Breast cancer is the most common cancer in women in
the USA, but it is a heterogeneous disease and treat-
ment recommendations vary accordingly. The expressions of
steroid hormone receptors such as estrogen receptor (ER)
and progesterone receptor (PR), and the oncogene ErbB-
2/human epidermal growth factor receptor 2 (HER-2) are
important factors in distinguishing breast cancer subtypes.
Triple negative breast cancer (TNBC), which is characterized
by a lack of ER, PR, and HER-2 expressions, comprises
approximately 11%–20%of all newly diagnosed breast cancers
[1–5]. Previous studies demonstrate that patients with TNBC
have a poorer outcome compared with other subtypes of
breast cancer [1, 6–10].The risk of recurrence for patientswith
TNBC peaks within the first 3 years following diagnosis and
treatment, and the majority of deaths take place within the
first 5 years after initial treatment [11–14].
Directed therapy options for treating TNBC are limited as
these tumors lack a therapeutic target that can be treated with
hormone therapy or trastuzumab. As a result, chemotherapy
is the standard method used to treat these patients [15–17].
Although randomized studies of neoadjuvant versus adjuvant
chemotherapy have failed to demonstrate a survival benefit
in either arm, complete pathologic response (pCR) following
neoadjuvant chemotherapy has been shown to be a good
prognostic marker for patient outcomes [16, 17].
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An accurate assessment of the extent of residual dis-
ease following neoadjuvant therapy is critical for surgical
decision-making.This is generally accomplished with a com-
bination of clinical breast examination with or without some
formof breast imaging,most commonly includingmammog-
raphy (MMG), ultrasonography (US), and/or magnetic res-
onance imaging (MRI). Although these imaging modalities
have been shown to be very effective in accurately measuring
the tumor size at the time of breast cancer diagnosis, their
accuracy in evaluating response to neoadjuvant therapy is
less clear [18–21]. We sought to investigate the accuracy
of MMG, US, and MRI in predicting the extent of breast
residual disease in patients with TNBC undergoing neoad-
juvant chemotherapy. We specifically selected this subtype
of breast cancer for two primary reasons. First, we were
interested in examining a population where pCR was likely
to be significantly higher, which would permit a comparative
evaluation of various imaging modalities at predicting pCRs.
Secondly, compared to other invasive malignancies, such as
invasive lobular cancer, TNBC tends to manifest more dis-
crete and quantifiable imaging features; specifically, they tend
to manifest as a mass, rather than architectural distortion
[22].
2. Materials and Methods
Institutional review board approval was obtained prior to the
commencement of this retrospective study.Written informed
consent of patients was not required.The prospectivelymain-
tained surgical database at Washington University/Barnes
Jewish Hospital was queried from January 1, 2000, to January
31, 2010 to identify all patients with a diagnosis of Stage
I–III biopsy-proven invasive TNBC. Patients were divided
according to receipt of neoadjuvant chemotherapy, adjuvant
chemotherapy, or none/unknown chemotherapy. All patients
who were clinically staged as having a Stage I–III TNBC and
who received neoadjuvant chemotherapy were included in
this study.The precise regimen of neoadjuvant chemotherapy
varied and was at the discretion of the treating medical
oncologist per the institutional standard of care.
Diagnostic imaging following neoadjuvant chemother-
apy was performed to evaluate tumor size after the last cycle
of chemotherapy, 1 to 4 weeks prior to surgical intervention.
The method of imaging was at the discretion of the treating
surgeon. Thus, not all patients were evaluated by imaging,
and some patients had a combination of imaging, including
MMG, US, and/or MRI. All diagnostic imaging was per-
formed at the Breast Health Center at the Alvin J. Siteman
Cancer Center. The Breast Health Center is fully certified
according to the federal Mammography Quality Standards
Act. Breast imaging examinations were performed using
standard techniques by one of our dedicated breast radiolo-
gists. For analysis purposes, the longestmeasured diameter of
residual tumor documented by any of the performed imaging
modalities was utilized as the final measure of residual tumor
prior to surgical intervention.
ER status, PR status, and HER-2/neu status were deter-
mined by core biopsy prior to systemic therapy. ER and PR
statuses were determined by standard immunohistochemical
methods. Tumors with less than 1% stained cells were consid-
ered to have negative receptor status. HER-2/neu status was
assessed by immunohistochemistry only if the results were
0 or 1+ staining and by fluorescence in situ hybridization
(FISH) confirmation if 2+ immunohistochemistry staining
was present. All patients included in the analysis had known
HER-2/neu status. Final pathologic assessment of tumor
residual volume was performed by 1 of 4 dedicated breast
pathologists. The tissue specimen was serially sectioned at
3 to 5mm intervals in the anteroposterior plane perpen-
dicular to the mediolateral axis and stained by hematoxylin
and eosin. Detailed examination was performed, including
documentation of the residual invasive or in situ tumor size, if
present. Patients were considered to have a pCR if no residual
invasive tumorwas present in the final pathology. For analysis
purposes, the longest measured diameter of residual invasive
tumor was utilized as the final pathologic tumor size.
Descriptive statistics were utilized for data summary.
Data were compared using Fisher’s exact and chi-squared
tests. All analyses were performed with SAS version 9
(SAS Institute, Cary, NC). 𝑃 values < 0.05 were considered
statistically significant.
3. Results
3.1. Study Population and Pathologic Outcomes. There were
493 patients with TNBC treated at our institution during
the study period. Of these, 148 patients had 151 Stage I–
III TNBCs treated with neoadjuvant chemotherapy; all met
the inclusion criteria and were considered evaluable. Table 1
provides the patient and tumor characteristics for the cohort.
Thirty-eight (25%) TNBCs experienced a pCR, while 113
(75%) final pathologies revealed residual invasive disease. Of
the 38 cases with a pCR, 33 were yT0N0 and 5 were yTisN0.
There were no differences between cases with a pCR and
those with residual disease on final pathology with respect
to patient age, race, pre-therapy clinical tumor size, tumor
grade, pretherapy clinical nodal status, or pretherapy clinical
stage (𝑃 > 0.05, Table 2). We were unable to determine the
posttherapy clinical tumor size clearly in the retrospective
chart review.
3.2. Imaging and Prediction of pCR. Of 151 tumors, 44 (29%)
were not imaged prior to surgical treatment, including 16
(36%) in which breast-conserving therapy was performed
and 28 (64%) in whichmastectomywas performed.Themost
common reason cited in the medical record for not perform-
ing imaging prior to surgical intervention was a planned
mastectomy (𝑁 = 28); the surgeons’ notes reflected that the
imaging would not alter the planned course. However, the
rationale for deferred imaging in the 16 patients undergoing
breast-conserving therapy is uncertain and the posttherapy
clinical stage was not reliably recorded.
The remaining 107 (71%) did have one or more imaging
studies performed following neoadjuvant chemotherapy but
prior to surgical treatment. For these 107 tumors, the method
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Table 1: Patient and tumor characteristics of 148 patients with 151
triple negative breast cancers treated with neoadjuvant chemother-
apy between 2000 and 2010.














Grade 1 2 (1)
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BCT: breast conservation therapy.
∗
𝑁 = 148 for patient characteristics (age, race, and neoadjuvant regimen
utilized) and 𝑁 = 151 for all tumor characteristics and type of surgical
intervention.
#Pathologic Stage 0 includes 33 cases with yT0N0 and 5 cases with yTisN0
final pathology.
$Nontaxane regimens included cisplatin- and epirubicin-based regimens.
of surgical intervention included 65 (61%) in which breast-
conserving therapy was performed and 42 (39%) in which
TNBC cases
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Figure 1: Imaging and pathologic outcomes of 148 patients with
151 Stage I–III triple negative breast cancers (TNBCs) undergoing
neoadjuvant chemotherapy prior to definitive surgical intervention.
mastectomy was performed. In the 38 cases where a pCR
was observed, imaging accurately predicted the pCR for 10
(26%) but residual disease was inaccurately suspected by
imaging in 20 (53%); imaging was not performed in 8 (21%).
Of 113 cases where residual invasive disease was seen on
final pathology, imaging accurately predicted the presence of
residual disease in 74 (65%), but inaccurately predicted a pCR
for 3 (3%); imaging was not performed in 36 (32%). There
were no differences between cases that were not imaged prior
to surgical treatment (𝑁 = 44) and those caseswhere imaging
was utilized prior to surgical treatment (𝑁 = 107) with
respect to patient age, race, pre-therapy clinical tumor size,
tumor grade, pre-therapy clinical nodal status, or pre-therapy
clinical stage (𝑃 > 0.05). Figure 1 illustrates the imaging and
pathologic outcomes of the 151 TNBC cases.
3.3. Imaging Accuracy. Overall, 107 TNBC cases underwent
one or more imaging studies prior to definitive surgical
therapy.The imagingmodalities utilized includedMMGonly
in 50 (47%), US only in 16 (15%), MRI only in 3 (3%), MMG
and US in 32 (30%), MMG and MRI in 2 (2%), US and MRI
in 2 (2%), and MMG, US, and MRI in 2 (2%). The imaging
modality accurately predicted the burden of final pathologic
residual disease to within 1 cm in 74 (69%, 95% CI 62–76%)
cases and to within 2 cm in 94 (88%, 95% CI 83–93%) cases.
Accuracy to within 1 cm was the highest for US (83%, 95%
CI 77–89%) and MRI (78%, 95% CI 71–85%), which were
significantly more accurate than MMG (56%, 95% CI 46–
64%) (𝑃 < 0.05).
Sensitivity and specificity calculations were performed in
the 38 patients with a pCR to determine whether a specific
imaging modality was superior in predicting this response.
Sensitivity and specificity calculations for MRI are limited by
the small sample size. No imagingmodality was superior with
respect to prediction of a pCR (sensitivity and specificity of
36% and 96% for US, 33% and 99% for MRI, and 28% and
87% for MMG; 𝑃 > 0.05).
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Table 2: Association of patient and tumor characteristics comparing residual disease versus no residual disease (pathologic complete




𝑛 = 113 (%)
pCR
𝑛 = 38 (%) P value
Age∗
<50 67 (61) 25 (66) NS
≥50 43 (39) 13 (34)
Race∗
Caucasian 66 (60) 20 (53)
African-American 41 (37) 16 (42) NS
Other 3 (3) 2 (5)
Clinical T stage
T1 16 (14) 6 (16)
T2 51 (45) 22 (58) NS
T3 37 (33) 10 (26)
Unknown 9 (8) 0 (0)
Nuclear grade
Grade 1 2 (2) 0 (0)
Grade 2 15 (13) 1 (3) NS
Grade 3 90 (80) 35 (92)
Unknown 6 (5) 2 (5)
Clinical N status
N0 43 (39) 19 (50)
N1 48 (42) 15 (39)
N2 7 (6) 3 (8) NS
N3 8 (7) 1 (3)
Unknown 7 (6) 0 (0)
Clinical Stage
1 6 (5) 4 (11)
2 58 (51) 25 (66) NS
3 38 (34) 7 (18)
Unknown 11 (10) 2 (5)
Neoadjuvant regimen#
Taxane-based 96 (85) 36 (95) NS
Nontaxane$ 17 (15) 2 (5)
∗
𝑁 = 148 for patients characteristics (age, race).
#
𝑁 = 151 overall but includes 3 patients with two cancer cases—all 3 received taxane-based regimens.
$Nontaxane regimens included cisplatin- and epirubicin-based regimens.
4. Discussion
TNBC is an aggressive form of breast cancer with a poorer
prognosis compared to other subtypes. However, TNBC
is particularly chemosensitive with high pCR rates in the
neoadjuvant setting compared to the other breast cancer
subtypes [6–10]. An accurate evaluation of residual disease
following neoadjuvant chemotherapy is necessary for surgical
planning, in order to best select candidates for breast conser-
vation and optimize cosmetic results. In the current study, we
evaluated the accuracy of MMG, US, and MRI in estimating
residual disease and predicting pCR for a cohort of patients
undergoing neoadjuvant chemotherapy for TNBC.We found
that US and MRI were superior to MMG in accurately
predicting the size of the residual invasive component. We
specifically restricted our analysis to this subtype of breast
cancer in order to maximize the number of patients likely
to experience a pCR and because the imaging findings are
typically more easily quantified than other subtypes of breast
cancer. Similar to other studies, we did observe a high
pCR rate of 25%, though no imaging study was superior in
predicting a pCR.
There currently is no clear consensus regarding the
best method for accurately assessing residual tumor size
Journal of Oncology 5
following neoadjuvant chemotherapy. Physical examination
alone has revealed mixed results. While several studies
report that physical examination is accurate in estimating
residual tumor size, other studies have shown that it is not
reliable [23, 24]. Physical examination is further limited
by the inability to distinguish irregular or poorly defined
margins or fibrosis/necrosis versus residual tumor. We were
unable to document the clinical stage following neoadjuvant
chemotherapy in this retrospective study. However, using
physical examination alone is limited in the modern era of
neoadjuvant chemotherapy administration, whereby many
patients have earlier disease and smaller tumors that may not
be reliably followed as response occurs. This is particularly
true for patients with TNBC who often have the most
dramatic responses clinically.
Thus, a reliable imaging modality is imperative. The
use of mammography and ultrasonography for measuring
residual tumor size after neoadjuvant chemotherapy has
been reported previously [23, 24]. Keune et al. [25] recently
compared the accuracy of mammography and ultrasonog-
raphy in predicting pathologic response after neoadjuvant
chemotherapy. Breast ultrasound was more accurate than
mammography; ultrasound was able to size the final disease
in 91.3% compared to only 51.9% when mammography was
used (𝑃 < 0.001). However, similar to our study, there was
no difference in the ability of mammography and ultrasound
to predict a pCR. Huber et al. [26] found that the accuracy
of mammography in predicting residual tumor disease may
depend on the initial mammographic appearance of the
tumor. For tumors whosemargins could be clearly delineated
from the adjacent breast tissue by more than 50% on the
baseline mammogram, the diagnostic reliability of posttreat-
ment mammography was high (𝑟 = 0.77). Ill-defined masses
on mammography had a lower correlation with the final
pathologic findings (𝑟 = −0.19) [26]. TNBC is typically
welldefined on mammography; however, MMGwas the least
accurate imaging modality in predicting residual tumor size
in our cohort of patients. One hypothesis is that the presence
of dead tumor may create a persistent density on MMG
accounting for this finding.
Compared with traditional breast imaging, MRI has been
shown to be more accurate in determining the local extent of
disease in newly diagnosed breast cancer [27]. Whether this
translates to a similarly higher rate of prediction of residual
disease following neoadjuvant chemotherapy administration
remains unclear. Data suggest that MRI is more accurate
compared with palpation and traditional breast imaging
in predicting response to neoadjuvant chemotherapy [28,
29]. However, as is the case when MRI is utilized for
initial evaluation of extent of disease, concerns over possible
overestimation of disease have also been reported [30].
Guarneri et al. [31] directly compared MRI and US in 108
patients undergoing neoadjuvant chemotherapy and found
no significant difference in the ability of MRI over US in
the prediction of residual disease (𝑟 = 0.53 and 𝑟 = 0.66,
resp.). In contrast, Yeh et al. [32] conducted a prospective
study comparing the relative accuracy of palpation, MMG,
US, and MRI (19%, 26%, 35%, and 71%, resp.; 𝑃 < 0.002) and
found MRI to be superior in predicting the final pathologic
disease burden. Further, they did not find any significant
tendency for under- or overestimation of disease between the
four approaches.
Our study has several limitations. This is a retrospective
study, and therefore inherent selection bias is difficult to
control. For instance, we cannot determine whether certain
neoadjuvant regimens influence response to therapy and
subsequent accuracy of the performed imaging. The most
common regimens were adriamycin and/or taxane based
but the cycle length and specifics of treatment were at the
discretion of the treating medical oncologist. Regardless,
this is a fair reflection of the chemotherapy practices to
date in the setting of TNBC. We also could not control the
frequency, consistency, or type of imaging used for each
patient.Themajor limitation of our analysis is the fact that the
numbers of MRI utilized overall were very low in our cohort.
Further, as we previously noted, a fair number of patients
did not have any final imaging prior to surgery, including
16 patients who underwent breast-conserving procedures.
It is unclear from the retrospective records how the final
surgical planningwas conducted; we presume that this was by
clinical examination alone, but we were unable to verify post-
therapy clinical tumor size retrospectively. Finally, all breast
imaging studies are read by dedicated breast radiologists
at our institution, likely improving the accuracy of every
imagingmodality utilized.Thus, our institutional results may
not be generalizable to other institutions.
5. Conclusions
In the current study, we found that US and MRI were
superior to MMG in accurately predicting residual disease.
However, no specific imaging modality was superior in
predicting a pCR. Further, the potential increased accuracy
of MRI must be counter-balanced with its increased cost
compared to traditional breast imaging, aswell as the need for
intravenous contrast administration. Because the utilization
ofMRI was very low in our cohort, further recommendations
regarding its use must be explored prospectively. In the
interim, we propose that breast US represents the most
accurate, affordable, noninvasive, and safe modality to assess
response to preoperative chemotherapy in patients with
TNBC. Prospective studies would be helpful in overcoming
the limitations of this and other retrospective analyses and in
determiningwhether themost viable imagingmodality varies
according to tumor biology.
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